Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib

Study ID
NCT02786342

Study type
Observational

Study phase

Study status
Unknown status

Trial Acronym

INNOVATE

Trial Summary

Sorafenib represents the standard care for advanced hepatocellular carcinoma (HCC). However, molecular predictors of sorafenib efficacy have not yet been identified. The primary aim of the study is to validate the prognostic or predictive role of eNOS,Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to clinical outcome (progression-free survival, PFS) of HCC patients treated with sorafenib.

More informations

Trial Starting Date

Feb 15,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

160